FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
-
-
-
-
-
-
-
Belite Bio begins FDA rolling submission for Stargardt disease treatment
-
-
-
-
-
-
-
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Starga
-
-
-
-
-
-
-
Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
-
-
-
-
-
-
-
Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007
-
-
-
-
-
-
-
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
-
326,554 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

